Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Technologies Appoints Ron Nersesian President and COO

Published: Thursday, November 15, 2012
Last Updated: Thursday, November 15, 2012
Bookmark and Share
The company's board of directors has appointed Ron Nersesian Agilent president and chief operating officer, effective immediately.

Nersesian has been executive vice president and chief operating officer since November 2011.

Nersesian, 53, will continue to be responsible for Agilent's Chemical Analysis (CAG), Life Sciences (LSG), Electronic Measurement (EMG), and Agilent Order Fulfillment (AOF) businesses, with the presidents of those groups reporting to him. Nersesian will continue to report to William (Bill) Sullivan, who remains chief executive officer.

Nersesian first joined Hewlett-Packard Co., Agilent's predecessor company, in 1984. Since then he has served in various management positions, including president of the electronic measurement business from 2009 to 2011.

Nersesian holds a bachelor's degree in electrical engineering from Lehigh University and an MBA from New York University, Stern School of Business.

"Ron is an outstanding global business leader," said Sullivan. "He transformed EMG when he headed that business, resulting in record profitable growth across current and emerging markets."

"Over the past year as COO, Ron made significant strides in increasing the profitability of our life science and chemical analysis businesses even as we navigated through a difficult economy," said Sullivan.

Sullivan added, "Ron's appointment as president and COO is an opportunity for Agilent to further leverage the skills of an executive with an exceptional record of business growth, cost improvements and superior return on invested capital."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent, Cell Line Genetics Collaborate
Companies to collaborate on high-throughput cell-line characterization services for regenerative medicine, cancer researchers.
Thursday, February 13, 2014
Agilent Debuts RNA Target Enrichment, Streamlining Transcriptome Profiling Studies to Advance Cancer and Stem Cell Research
Company has introduced SureSelect RNA Capture Kits, enabling geneticists to focus on specific genomic loci or transcripts of research interest.
Wednesday, February 09, 2011
Agilent and Stemina Announce Efforts to Accelerate Stem Cell Metabolite Biomarker Discovery
Agilent to provide a 1290 Infinity UHPLC system to separate stem cellular metabolites, coupled to a 6530 Accurate Mass Q-TOF MS to identify those metabolites.
Wednesday, June 02, 2010
Novel Automated Stem Cell High Content Screening Platform
A new technical poster describes how researchers at I-STEM have used a BioCel 1800 platform for muscular dystrophy therapeutic research.
Friday, June 19, 2009
Agilent Technologies Adds Custom miRNA Capability to Online Microarray Design Tool
The eArray 5.4 online microarray design tool will enable users to design custom microRNA microarrays.
Thursday, January 15, 2009
Agilent Tools Used to Derive new Type of Mouse Embryonic Stem Cell
Using a variety of Agilent's genomics tools, researchers have achieved a major milestone in solving some of the perplexing differences between embryonic stem cells of humans and mice.
Friday, July 27, 2007
Scientific News
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
New Material Forges the Way for 'Stem Cell Factories'
Researchers have discovered the first fully synthetic substrate with potential to grow billions of stem cells. The researchcould forge the way for the creation of 'stem cell factories' - the mass production of human embryonic (pluripotent) stem cells.
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
'Google Maps' for the Body
Scientists have revealed research that uses previously top-secret technology to zoom through the human body down to the level of a single cell that could be a game-changer for medicine.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!